ホーム › 乳がん › コロンビア特別区 › Washington
Washington、DCにおける乳がんの臨床試験
Washingtonとその周辺地域（約30マイル以内）の拠点で、乳がんに関する46件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
被験者募集中観察研究
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
The Vanguard Study: Testing a New Way to Screen for Cancer
被験者募集中健康なボランティア歓迎
- Walter Reed National Military Medical Center, Bethesda · 7マイル先
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
被験者募集中第3相
- Georgetown University Medical Center, Washington D.C.
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
被験者募集中第2相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
被験者募集中観察研究
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
被験者募集中第3相
- Georgetown University Lombardi Cancer Center, Washington D.C.
- Maryland Oncology Hematology P A, Silver Spring · 7マイル先
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- Walter Reed National Military Medical Center, Bethesda · 7マイル先
Genomic Services Research Program
被験者募集中観察研究
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Older Breast Cancer Patients: Risk for Cognitive Decline
被験者募集中観察研究健康なボランティア歓迎
- Georgetown University, Washington D.C.
Collection of Blood From Patients With Cancer
被験者募集中観察研究健康なボランティア歓迎
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
被験者募集中第2相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
被験者募集中第3相
- Holy Cross Hospital ( Site 0073), Silver Spring · 7マイル先
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
被験者募集中第2相
- The George Washington Medical facility Associates, Washington D.C.
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- MedStar Washington Hospital Center, Washington D.C.
- American Oncology Partners, PA, Bethesda · 7マイル先
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
被験者募集中第3相
- Georgetown Uni Hospital, Washington D.C.
- Medstar Research Institute, Hyattsville · 6マイル先
Identifying Patterns in the Breath of Individuals With Breast Cancer
被験者募集中観察研究健康なボランティア歓迎
- GW Comprehensive Breast Center, Washington D.C.
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Georgetown University Medical Center, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- Sibley Memorial Hospital, Washington D.C.
- 他1件
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
被験者募集中第1相
- MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center, Washington D.C.
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
被験者募集中第1/2相
- Georgetown University, Washington D.C.
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
被験者募集中第3相
- The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A., Bethesda · 7マイル先
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- 他5件
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
被験者募集中第2相
- Georgetown University Medical Center, Washington D.C.
A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
被験者募集中
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming
被験者募集中
- Sibley Memorial Hospital, Washington D.C.
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
被験者募集中第3相
- Sibley Memorial Hospital, Washington D.C.
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
被験者募集中第1/2相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
被験者募集中
- Walter Reed National Military Medical Center, Bethesda · 7マイル先
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
被験者募集中第3相
- Johns Hopkins Medicine - Kimmel Cancer Center-Sibley Memorial Hospital, Washington D.C.
E-Mindfulness Approaches for Living After Breast Cancer
被験者募集中第3相
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- 他2件
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
被験者募集中観察研究健康なボランティア歓迎
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
被験者募集中第2相
- National Institute of Health Clinical Center, Bethesda · 7マイル先
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
被験者募集中第3相
- American Oncology Partners, P.A., Bethesda · 7マイル先
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
被験者募集中第2相
- Georgetown University Medical Center, Washington D.C.
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
被験者募集中第3相
- MedStar Washington Hospital Center, Washington D.C.
- Maryland Oncology Hematology P.A., Silver Spring · 7マイル先
- Maryland Oncology Hematology P.A., Bethesda · 7マイル先
- 他1件
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
被験者募集中第3相
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- George Washington University Medical Center, Washington D.C.
- 他2件
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
被験者募集中観察研究健康なボランティア歓迎
- Cancer Support Community Research & Training Institute, Washington D.C.
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
被験者募集中第2相
- Georgetown University, Washington D.C.
Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
被験者募集中第2相
- George Washington-Medical Faculty Associates, Washington D.C.
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
被験者募集中
- Sibley Memorial Hospital, Washington D.C.
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
被験者募集中観察研究
- Holy Cross Hospital - Silver Spring, Silver Spring · 7マイル先
- The Center for Cancer and Blood Disorders - Bethesda, Bethesda · 7マイル先
Study in Patients With Breast Cancer Leptomeningeal Metastasis
被験者募集中観察研究
- Sibley Memorial Hospital, Washington D.C.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Silver Spring · 7マイル先
- Massive Bio SYNERGY-AI site, Bethesda · 7マイル先
The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
被験者募集中
- Georgetown University, Washington D.C.
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
被験者募集中健康なボランティア歓迎
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
被験者募集中観察研究
- Maryland Oncology Hematology, PA, Silver Spring · 7マイル先
- Maryland Oncology Hematology - Bethesda, Bethesda · 7マイル先
CtDNA Based MRD Testing for NAC Monitoring in TNBC
被験者募集中観察研究
- George Washington University, Washington D.C.
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Washingtonにおける他の研究
- がん（全種類）58件の研究
- 非小細胞肺癌55件の研究
- 転移性癌43件の研究
- 肺がん41件の研究
- 前立腺がん38件の研究
- 肥満症33件の研究
- 大腸癌29件の研究
- 心血管疾患28件の研究
- 膀胱癌26件の研究
- 急性骨髄性白血病24件の研究
- 卵巣がん23件の研究
- リンパ腫23件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。